“Elotuzumab: the first available immunotherapeutic arrow against relapsed-refractory Multiple Myeloma”, Eur J Oncol, vol. 22, no. 2, pp. 65–70, Nov. 2017, Accessed: Jul. 18, 2024. [Online]. Available: https://mattioli1885journals.com/index.php/EJOEH/article/view/6857